About the Authors

Anita K. Gandhi

agandhi@celgene.com

Affiliation Department of Translational Development, Celgene Corporation, Summit, New Jersey, United States of America

Tao Shi

Affiliation Department of Scientific Information Systems, Celgene Corporation, San Diego, California, United States of America

Mingyu Li

Affiliation Department of Biostatistics and Programming, Celgene Corporation, Summit, New Jersey, United States of America

Ulf Jungnelius

Affiliation Clinical Research and Development, Celgene, Summit, New Jersey, United States of America

Alfredo Romano

Affiliation Clinical Research and Development, Celgene, Summit, New Jersey, United States of America

Josep Tabernero

Affiliation Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain

Salvatore Siena

Affiliation Ospedale Niguarda Ca' Granda, Milan, Italy

Peter H. Schafer

Affiliation Department of Translational Development, Celgene Corporation, Summit, New Jersey, United States of America

Rajesh Chopra

Affiliation Department of Translational Development, Celgene Corporation, Summit, New Jersey, United States of America

Competing Interests

Anita Gandhi, Tao Shi, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Peter Schafer, and Rajesh Chopra are employees of Celgene Corporation, whose company funded this study. Salvatore Siena is a member of advisory boards for Sanofi-Aventis, AstraZeneca, Roche, Genentech, Celgene, Genomic Health, Bayer, and Amgen. Josep Tabernero has participated in advisory boards for Amgen, Celgene, Genentech, Merck-Serono, Novartis, Roche, Sanofi- Aventis, and Symphogen. Lenalidomide (Revlimid®) is a marketed Celgene product. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: UJ AR JT SS. Analyzed the data: AKG TS ML. Wrote the paper: AKG RC. Trial design and conduct: UJ AR JT SS. Intellectual input and data analysis support: PS.